Michael Bart Sheffery

Michael Bart Sheffery

Director/Board Member at
Eximias Pharmaceutical Corp.
75 year
Health Technology
Finance
Consumer Services

Profile

Dr. Michael B. Sheffery is Partner Emeritus at OrbiMed Advisors LLC.
He joined the firm in 1989.
In addition to that, he is General Partner at OrbiMed Advisors Private Equity.
He is on the Board of Directors at Biosynexus, Inc., Eximias Pharmaceutical Corp., CoGenesys, Inc., Affimed Therapeutics AG, Pieris AG, and arGEN-X BV.
Dr. Sheffery was previously employed as Independent Director by Athersys, Inc., Independent Director by Supernus Pharmaceuticals, Inc., and Head-Laboratory by New York Cancer Hospital.
He also served on the board at BTHC VI, Inc., Memory Pharmaceuticals Corp., and NeoGenesis Pharmaceuticals, Inc. Dr. Sheffery received both his PhD in Molecular Biology and his BA in Biology from Princeton University.
He joined Mehta and Isaly in 1996 as a Senior Analyst covering the biotechnology industry.

Michael Bart Sheffery active positions

CompaniesPositionStart
Director/Board Member -
Director/Board Member -
Private Equity Investor -

Former positions of Michael Bart Sheffery

CompaniesPositionEnd
SUPERNUS PHARMACEUTICALS, INC. Director/Board Member 29/10/2012
ATHERSYS, INC. Director/Board Member 09/09/2010
Director/Board Member 06/09/2007
Corporate Officer/Principal 14/01/2003
AFFIMED N.V. Director/Board Member -
See the detail of Michael Bart Sheffery's experience

Training of Michael Bart Sheffery

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

68

1st degree connections

15

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies15

Health Technology

Health Technology

Finance

Health Technology

Health Technology

Consumer Services

Health Technology

Health Technology

Health Services

Health Technology

Health Technology

Health Technology

Finance

Health Technology

Health Technology

  1. Stock Market
  2. Insiders
  3. Michael Bart Sheffery
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!